Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.
Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.
复制标题
氨甲酰化促红细胞生成素不能减轻 mdx 小鼠的营养不良症状。
DOI：
10.1002/mus.21785
复制
发表时间：
2011
期刊：
影响因子：
3.4
通讯作者：
Gussoni,Emanuela
中科院分区：
文献类型：
--
作者：
Wu,MelissaP;Gussoni,Emanuela
促红细胞生成素促进成肌细胞增殖，抑制纤维化，从而可以阻止肌肉退行性疾病的发病机制。然而，其刺激红细胞生成限制了其作为治疗剂的用途。促红细胞生成素类似物，氨甲酰化促红细胞生成素（C-EPO），保留这些保护作用，但它不与促红细胞生成素受体相互作用。为了确定C-EPO治疗是否能减轻Duchenne型肌营养不良症动物模型的肌营养不良症症状，我们对mdx小鼠腹腔注射50 μg/kg和100 μg/kg C-EPO治疗4周和12周，并监测体重、血清肌酸激酶水平和肌肉组织学变化。在4周时观察到中度组织学改善，这并未转化为血清肌酸激酶水平的显著降低。在测试的剂量下，C-EPO不是治疗杜氏肌营养不良症小鼠模型的有效治疗剂。肌肉神经，2011年
Erythropoietin promotes myoblast proliferation and inhibits fibrosis and thus it could impede the pathogenesis of muscle degenerative diseases. However, its stimulation of erythropoiesis limits its use as a therapeutic agent. An erythropoietin analog, carbamylated erythropoietin (C‐EPO), retains these protective actions, yet it does not interact with the erythropoietin receptor. To determine whether treatment with C‐EPO alleviates the signs of muscular dystrophy in an animal model of Duchenne muscular dystrophy, we treatedmdxmice with intraperitoneal injections of 50 μg/kg and 100 μg/kg C‐EPO for 4 and 12 weeks, and we monitored weight, serum creatine kinase levels, and changes in muscle histology. Moderate histological improvement was observed at 4 weeks, which did not translate into a significantly decreased level of serum creatine kinase. At the doses tested, C‐EPO is not an effective therapeutic for the treatment of a mouse model of Duchenne muscular dystrophy. Muscle Nerve, 2011